WASHINGTON (AP) — President Donald Trump unveiled a deal Thursday with drugmakers Eli Lilly and Novo Nordisk to expand coverage and reduce prices for the popular obesity treatments Zepbound and Wegovy.

Known as GLP-1 receptor agonists, the drugs have soared in popularity in recent years but patient access has been a consistent problem because of their cost — around $500 a month for higher doses — and insurance coverage has been spotty. More than 100 million American adults have obesity, according to federal estimates.

Copyright 2025 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed without permission. kAmr@G6C286 @7 E96 5CF8D 7@C @36D:EJ H:== 6IA2?5 E@ |65:42C6 A2E:6?ED DE2CE:?8 ?6IE J62C[ 244@C5:?8 E@ E96 25>:?:DEC2E:

See Full Page